Search Results

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the BIO International Convention, taking place June 3-6, 2024, in San Diego, CA.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 2024 BIO CEO & Investor Conference, taking place February 26-27, 2024, in New York, NY.

Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the first quarter ended March 31, 2024 and summarized recent business highlights.

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present new pharmacology data on brilaroxazine as part of two poster presentations at the ASPET 2024 Annual Meeting, to be held in Arlington, VA May 16-19, 2024.

Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a Fireside Chat at the UBS Virtual CNS Day, taking place virtually March 18, 2024.

Reviva Pharmaceuticals Holdings, Inc. today announced an enrollment update to the ongoing 1-year open-label extension (OLE) study evaluating the long-term safety and tolerability of brilaroxazine in patients with schizophrenia.

Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the 36th Annual ROTH Conference, taking place March 17-19, 2024.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the full year ended December 31, 2023 and summarized recent business highlights.